Settings
Save and close
The Jackson Laboratory (JAX) Preclinical Services provides cutting-edge solutions for Metabolism Research including anti-obesity and diabetes drugs, offering a comprehensive range of in vivo metabolic phenotyping services tailored to support preclinical drug discovery and translational studies. Our validated DIO Mice and other specialized Metabolism Mice models enable detailed investigation of disease pathology, metabolic dysfunction, and therapeutic strategies, making them a powerful platform for drug discovery and target validation.
With our advanced phenotyping capabilities and deep scientific expertise, JAX is poised to help researchers drive forward metabolism research and accelerate the development of innovative treatments for diabetes, obesity, and other metabolic disorders.
Our Expertise
JAX Preclinical Services applies its extensive expertise in metabolic research—focusing on diabetes, obesity, and metabolic disorders—to develop robust study designs that advance drug development and enhance therapeutic success.
Chronic and acute dosing studies to assess drug efficacy in mouse models of metabolic disease.
Examination of pancreatic tissue through histological analysis (H&E), including:
Comprehensive body composition analysis, including:
Assessment of:
Metabolic assessment through indirect calorimetry, including:
JAX Preclinical Services are managed by highly trained study directors and staff to assist you in obtaining the data necessary for your research. Below, you will find an introduction to an example study; however, studies can be tailored to meet your specific research requirements. To access additional information and more sample metabolic studies, please click the button below.
Body weight trajectories (g) during treatment and post-withdrawal. Vehicle-treated mice maintained stable weight, while Semaglutide and Tirzepatide reduced body weight by ~7% and ~30%, respectively. Upon withdrawal, Semaglutide and Tirzepatide groups regained ~5% and ~20% of body weight.
Fat mass (g) after 4 weeks of treatment. Semaglutide reduced fat mass by 16%, while Tirzepatide induced a 62% reduction.
In vivo 3D microCT imaging of adipose and lean tissue (Quantum GX, PerkinElmer) after 4 weeks of treatment. Adipose depots were segmented based on density and outlined manually using ImageJ. Subcutaneous fat is shown in green, visceral fat in red, and lean mass in blue. Both treatments reduced subcutaneous and visceral adiposity. n = 8-9 per group.
Lean mass changes (%). Lean mass increased by 2.5% in Vehicle controls, but declined by 1% and 7.8% with Semaglutide and Tirzepatide, respectively.
With so many models available, choosing the most appropriate mouse model for your metabolic study can be challenging. During this webinar, we discuss the strengths and limitations of popular mouse models of human type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH).
Not what you're looking for?
Visit our Resource Hub
